Revel Pharmaceuticals
PrivateLast Round
Grant
Aug 15, 2023
Total Funding Raised
$8.95M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Revel Pharmaceuticals operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was a Grant round in August 2023.
Revel Pharmaceuticals is a biotechnology company developing therapeutic enzymes designed to degrade molecular damage associated with aging.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Government Contracts, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Revel Pharmaceuticals Comparables
Compare Revel Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Lento Bio, Inc. | 74% | |
| Oisín Biotechnologies | 71% | |
| Rejuvenation Technologies | 71% |
For institutional investors. Book with your work email.
Revel Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Aug 15, 2023 | ||||
| Seed | Mar 17, 2022 | ||||
| Seed | Jan 7, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Revel Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Kizoo Technology Capital | Seed |
| Starbloom Capital | Seed |
| NIH RADx | Grant |
| Tubus LLC | Seed |
| National Institute on Aging | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 270% MoM, reaching 9.8K.
- Mar 1, 2026
Monthly visitors increased 267% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withOct 17, 2026
Revelpharmaceuticals and CU collaborate on a breakthrough described in a July '26 Nature Communications paper about the laboratory-developed enzyme CMLase.
For institutional investors. Book with your work email.
Revel Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Revel Pharmaceuticals's valuation, stock price, and market status.
Is Revel Pharmaceuticals a public or private company?
Revel Pharmaceuticals is a private company.
What is the current stock price of Revel Pharmaceuticals?
Revel Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Revel Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Revel Pharmaceuticals worth (valuation)?
Valuation information for Revel Pharmaceuticals is not publicly available.
Can I buy Revel Pharmaceuticals stock?
Revel Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Revel Pharmaceuticals's last funding round?
Revel Pharmaceuticals's most recent funding round was Grant on August 15, 2023.
Who are the main investors in Revel Pharmaceuticals?
Key investors in Revel Pharmaceuticals include Kizoo Technology Capital, Starbloom Capital.
Will Revel Pharmaceuticals IPO soon?
No public IPO plans have been announced for Revel Pharmaceuticals.
How can I track Revel Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Revel Pharmaceuticals's shares on secondary markets.